title: Absence of embryo-fetal toxicity in rats or rabbits following oral dosing with nelfinavir.
abstract: The potential for nelfinavir mesylate (VIRACEPT) to induce maternal and embryo-fetal toxicity was evaluated in rats and rabbits following oral administration. The drug was administered by gavage to rats at doses of 200, 500, or 1000mg/kg/day on days 6-17 of gestation and to rabbits at doses of 200, 400, or 1000mg/kg/day on days 7-20 of gestation. Dams and does were euthanized on GD20 and 29, respectively, and the offspring were weighed and examined for external, visceral, and skeletal alterations. Maximum plasma nelfinavir concentrations (C(max)) in rats were comparable to C(max) values in humans and were 3- to 6-fold higher than the reported human trough levels, while plasma nelfinavir levels in rabbits were approximately 0.13-0.17x the human C(max) and 0.25-0.5x the human trough. In rats, no treatment-related maternal or embryo-fetal toxicity was observed at any dose level and the NOAEL for both maternal and fetal toxicity was considered to be 1000mg/kg/day. Two rabbits in the 400mg/kg/day group died prior to scheduled termination. Because no deaths occurred in the high dose group and there were no other treatment-related signs of clinical toxicity in any dose group, these deaths were considered unrelated to nelfinavir. Group mean body weight loss in rabbits was observed at 1000mg/kg/day on gestation days 7-10. Food consumption was also reduced in this treatment group throughout the dosing period. There were no treatment-related findings in other maternal or fetal parameters. Thus, the no-observed-adverse-effect-level (NOAEL) for maternal toxicity in the rabbit was considered to be 400mg/kg/day (based on maternal body weight loss in the high dose group), while the NOAEL for embryo-fetal toxicity in the rabbit was considered to be 1000mg/kg/day. Thus, under the conditions of this study, nelfinavir was not considered to be toxic to the rat or rabbit conceptus.
authors: Worldwide Safety Sciences, Pfizer Global Research and Development, La Jolla Laboratories, San Diego, CA, USA. leighann.burns@pfizer.com
authors: Leigh Ann
authors: LA
authors: Burns-Naas
authors: Stephanie
authors: S
authors: Webber
authors: Donald G
authors: DG
authors: Stump
authors: Joseph F
authors: JF
authors: Holson
authors: Lilit
authors: L
authors: Masarjian
authors: Mark
authors: M
authors: Zorbas
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000831:Animals, Newborn / Q000033:anatomy & histology / Q000502:physiology; D004353:Drug Evaluation, Preclinical / Q000379:methods; D005314:Embryonic and Fetal Development / Q000187:drug effects* / Q000502:physiology*; D005260:Female; D005333:Fetus / Q000002:abnormalities / Q000187:drug effects; D008431:Maternal-Fetal Exchange / Q000187:drug effects / Q000502:physiology; D019888:Nelfinavir / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity*; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000187:drug effects / Q000502:physiology; D011817:Rabbits; D051381:Rats
chemical_list: D019888:Nelfinavir